Three-year follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PDL1, as second-line (2L) treatment of advanced non-small cell lung cancer (NSCLC)

by on 15 de març de 2021 with No hi ha comentaris
  • Paz-Ares, L., Kim, T. M., Vicente, D., Felip, E., Lee, D. H., Lee, K. H., et al. (2021). Three-year follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PDL1, as second-line (2L) treatment of advanced non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology, 16(1), S26-S27. https://doi.org/10.1016/j.jtho.2020.10.132

Deixa un comentari

L'adreça electrònica no es publicarà. Els camps necessaris estan marcats amb *